<DOC>
	<DOCNO>NCT00426140</DOCNO>
	<brief_summary>The main purpose study characterize distribution , metabolism , elimination ( ADME ) Patupilone single intravenous administration patient advance solid tumor malignancy</brief_summary>
	<brief_title>Pharmacokinetics Patupilone After Single Intravenous Administration Patients With Advance Solid Tumor Malignancies .</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Epothilone B</mesh_term>
	<mesh_term>Epothilones</mesh_term>
	<criteria>1 . 18 year old 2 . World Health Organization ( WHO ) Performance Status Score : 0 fully active less illness , 1 carry heavy physical work , anything else . 3 . Adequate hematological laboratory parameter 4 . No major impairment renal hepatic function 5 . Female patient must negative serum pregnancy test screening . 1 . Severe and/or uncontrolled medical disease ; 2 . Severe cardiac insufficiency uncontrolled and/or unstable cardiac coronary artery disease ; 3 . Known diagnosis human immunodeficiency virus ( HIV ) infection ; 4 . Presence active suspect acute chronic uncontrolled infection ; 5 . Symptomatic brain metastasis leptomeningeal disease . Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>EPO</keyword>
	<keyword>Patupilone</keyword>
	<keyword>Solid Tumors</keyword>
</DOC>